Knowledge, Attitudes, and Behavior Related to COVID-19 Testing: A Rapid Scoping Review
Abstract
:1. Introduction
2. Materials and Methods
Literature Search
3. Results
3.1. Overview of Studies
3.2. Scope of Research
4. Thematic Findings
4.1. Acceptability, Uptake, and Barriers to Testing
4.1.1. Test Knowledge and Symptom Interpretation
4.1.2. Perceived Benefits of Testing
4.1.3. Logistics of Testing
4.1.4. Social Solidarity, Peer-Pressure, and Stigma
4.1.5. Financial Burden of Testing
4.1.6. Trust
4.1.7. Vulnerable Groups
4.2. Impact of Testing on Attitudes, Behaviors, and Wellbeing
4.2.1. Mental Health and Wellbeing
4.2.2. Adherence to Guidelines
5. Reported Limitations of Included Studies
6. Discussion
6.1. Thematic Analysis and Recommendations
6.2. Limitations of the Review
7. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- World Health Organization Laboratory Testing Strategy Recommendations for COVID-19. Available online: https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf (accessed on 12 July 2021).
- Zitek, T. The appropriate use of testing for Covid-19. West. J. Emerg. Med. 2020, 21, 470–472. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Atkeson, A.; Droste, M.C.; Mina, M.; Stock, J.H. Economic Benefits of COVID-19 Screening Tests; National Bureau of Economic Research: Cambridge, MA, USA, 2020. [Google Scholar] [CrossRef]
- Binnicker, M.J. Challenges and controversies to testing for COVID-19. J. Clin. Microbiol. 2020, 58, e01695-20. [Google Scholar] [CrossRef]
- Tromberg, B.J.; Schwetz, T.A.; Pérez-Stable, E.J.; Hodes, R.J.; Woychik, R.P.; Bright, R.A.; Fleurence, R.L.; Collins, F.S. Rapid Scaling Up of Covid-19 Diagnostic Testing in the United States—The NIH RADx Initiative. N. Engl. J. Med. 2020, 383, 1071–1077. [Google Scholar] [CrossRef] [PubMed]
- Street, A.; Bevan, I.; Lee, S.; Taylor, M.; Templeton, K. Testing and Trust: Public Perceptions, Expectations, and Experiences of COVID-19 Testing in Scotland. Available online: https://www.cso.scot.nhs.uk/wp-content/uploads/COVEDI2018-1.pdf (accessed on 1 September 2021).
- Beeching, N.J.; Fletcher, T.E.; Beadsworth, M.B.J. Covid-19: Testing times. BMJ 2020, 369, m1403. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weissleder, R.; Lee, H.; Ko, J.; Pittet, M.J. COVID-19 diagnostics in context. Sci. Transl. Med. 2020, 12, 1931. [Google Scholar] [CrossRef]
- Gandhi, D.; Landage, S.; Bae, J.; Shankar, S.; Sukumaran, R.; Patwa, P.; Sethuraman, T.V.; Katiyar, P.; Advani, S.; Iyer, R.; et al. Clinical Landscape of COVID-19 Testing: Difficult Choices. arXiv 2020, arXiv:2011.04202. [Google Scholar]
- Iacobucci, G. Covid-19: What is the UK’s testing strategy? BMJ 2020, 368, m1222. [Google Scholar] [CrossRef] [Green Version]
- Raffle, A.E.; Pollock, A.M.; Harding-Edgar, L. Covid-19 mass testing programs. BMJ 2020, 370, m3262. [Google Scholar] [CrossRef]
- Burki, T.K. Testing for COVID-19. Lancet Respir. Med. 2020, 8, e63–e64. [Google Scholar] [CrossRef]
- Harahwa, T.A.; Yau, T.H.L.; Lim-Cooke, M.-S.; Al-Haddi, S.; Zeinah, M.; Harky, A. The optimal diagnostic methods for COVID-19. Diagnosis 2020, 7, 349–356. [Google Scholar] [CrossRef] [PubMed]
- Street, A.; Kelly, A. Counting Coronavirus: Delivering Diagnostic Certainty in a Public Health Emergency. Somatosphere 2020, 6. Available online: http://somatosphere.net/forumpost/counting-coronavirus-diagnostic-certainty-global-emergency/ (accessed on 1 September 2021).
- Bavel, J.J.V.; Baicker, K.; Boggio, P.S.; Capraro, V.; Cichocka, A.; Cikara, M.; Crockett, M.J.; Crum, A.J.; Douglas, K.M.; Druckman, J.N.; et al. Using social and behavioural science to support COVID-19 pandemic response. Nat. Hum. Behav. 2020, 4, 460–471. [Google Scholar] [CrossRef] [PubMed]
- Reicher, S.; Drury, J. Pandemic fatigue? How adherence to covid-19 regulations has been misrepresented and why it matters. BMJ 2021, 372, n137. [Google Scholar] [CrossRef]
- Kubina, R.; Dziedzic, A. Molecular and serological tests for COVID-19. A comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. Diagnostics 2020, 10, 434. [Google Scholar] [CrossRef]
- Grant, M.J.; Booth, A. A typology of reviews: An analysis of 14 review types and associated methodologies. Health Info. Libr. J. 2009, 26, 91–108. [Google Scholar] [CrossRef]
- Arksey, H.; O’Malley, L. Scoping studies: Towards a methodological framework. Int. J. Soc. Res. Methodol. Theory Pract. 2005, 8, 19–32. [Google Scholar] [CrossRef] [Green Version]
- Ritchie, J.; Spencer, L. Qualitative data analysis for applied policy research. In Analyzing Qualitative Data; Routledge: London, UK, 2002; pp. 187–208. [Google Scholar]
- Weiss, D.; Crooks, M.; Goorland, L.; Elwood, D. Limiting Potential Exposure During a Pandemic: The Importance of Diagnostic Testing Options for COVID-19. Telemed. e-Health 2020, 27, 1074–1077. [Google Scholar] [CrossRef]
- Denford, S.; Martin, A.F.; Love, N.; Ready, D.; Oliver, I.; Amlôt, R.; Yardley, L.; Rubin, G.J. Engagement With Daily Testing Instead of Self-Isolating in Contacts of Confirmed Cases of SARS-CoV-2: A Qualitative Analysis. Front. Public Health 2021, 9, 714041. [Google Scholar] [CrossRef]
- Blake, H.; Corner, J.; Cirelli, C.; Hassard, J.; Briggs, L.; Daly, J.M.; Bennett, M.; Chappell, J.G.; Fairclough, L.; McClure, C.P.; et al. Perceptions and experiences of the university of nottingham pilot sars-cov-2 asymptomatic testing service: A mixed-methods study. Int. J. Environ. Res. Public Health 2021, 18, 188. [Google Scholar] [CrossRef]
- Watson, D.; Baralle, N.L.; Alagil, J.; Anil, K.; Ciccognani, S.; Dewar-Haggart, R.; Fearn, S.; Groot, J.; Knowles, K.; Meagher, C.; et al. How best do we engage the general population in testing for COVID-19. medRxiv 2021. [Google Scholar] [CrossRef]
- Gillam, T.B.; Cole, J.; Gharbi, K.; Angiolini, E.; Barker, T.; Bickerton, P.; Brabbs, T.; Chin, J.; Coen, E.; Cossey, S.; et al. Norwich COVID-19 testing initiative pilot: Evaluating the feasibility of asymptomatic testing on a university campus. J. Public Health 2021, 43, 82–88. [Google Scholar] [CrossRef]
- Packel, L.; Reingold, A.; Hunter, L.; Facente, S.; Li, Y.; Harte, A.; Nicolette, G.; Urnov, F.D.; Lu, M.; Petersen, M. Piloting an integrated SARS-CoV-2 testing and data system for outbreak containment among college students: A prospective cohort study. PLoS ONE 2021, 16, e0245765. [Google Scholar] [CrossRef] [PubMed]
- Blake, H.; Knight, H.; Jia, R.; Corner, J.; Morling, J.R.; Denning, C.; Jk, B.; Bolton, K.; Figueredo, G.; Morris, D.; et al. Students’ views towards sars-cov-2 mass asymptomatic testing, social distancing and self-isolation in a university setting during the covid-19 pandemic: A qualitative study. Int. J. Environ. Res. Public Health 2021, 18, 4182. [Google Scholar] [CrossRef] [PubMed]
- Christensen, S.W.; Dagyaran, I.; Bernild, C.; Missel, M.; Berg, S.K. Testing for COVID-19 regulates behavior in the general population: A qualitative study of experiences of awaiting test result for COVID-19. Scand. J. Public Health 2021, 1403494821993717. [Google Scholar] [CrossRef]
- Rojek, A.; Dutch, M.; Peyton, D.; Pelly, R.; Putland, M.; Hiscock, H.; Knott, J. Patients presenting for hospital-based screening for the coronavirus disease 2019: Risk of disease, and healthcare access preferences. Emerg. Med. Australas. 2020, 32, 809–813. [Google Scholar] [CrossRef]
- Graham, M.S.; May, A.; Varsavsky, T.; Sudre, C.H.; Murray, B.; Kläser, K.; Antonelli, M.; Canas, L.S.; Molteni, E.; Modat, M.; et al. Knowledge barriers in the symptomatic-COVID-19 testing programme in the UK: An observational study. medRxiv 2021. [Google Scholar] [CrossRef]
- Allen, W.E.; Altae-Tran, H.; Briggs, J.; Jin, X.; McGee, G.; Shi, A.; Raghavan, R.; Kamariza, M.; Nova, N.; Pereta, A.; et al. Population-scale longitudinal mapping of COVID-19 symptoms, behaviour and testing. Nat. Hum. Behav. 2020, 4, 972–982. [Google Scholar] [CrossRef]
- Ravert, R.D.; Fu, L.Y.; Zimet, G.D. Young Adults’ COVID-19 Testing Intentions: The Role of Health Beliefs and Anticipated Regret. J. Adolesc. Health 2021, 68, 460–463. [Google Scholar] [CrossRef] [PubMed]
- Missel, M.; Bernild, C.; Dagyaran, I.; Christensen, S.W.; Berg, S.K. A stoic and altruistic orientation towards their work: A qualitative study of healthcare professionals’ experiences of awaiting a COVID-19 test result. BMC Health Serv. Res. 2020, 20, 1031. [Google Scholar] [CrossRef]
- Bender, W.R.; Srinivas, S.; Coutifaris, P.; Acker, A.; Hirshberg, A. The Psychological Experience of Obstetric Patients and Health Care Workers after Implementation of Universal SARS-CoV-2 Testing. Am. J. Perinatol. 2020, 37, 1271–1279. [Google Scholar] [CrossRef] [PubMed]
- Kawamura, H.; Orisaka, M.; Yoshida, Y. Mentality of pregnant women and obstetric healthcare workers about prenatal SARS-CoV-2 testing: A regional survey over the first wave of the COVID-19 pandemic in Japan. J. Obstet. Gynaecol. Res. 2021, 47, 1763–1771. [Google Scholar] [CrossRef] [PubMed]
- Lan, R.; Sujanto, R.; Lu, K.; He, Z.; Zhang, C.J.P.; Ming, W.K. Perceived Effectiveness, Safety, and Attitudes Toward the Use of Nucleic Tests of SARS-CoV-2 Among Clinicians and General Public in China. Front. Public Health 2020, 8, 819. [Google Scholar] [CrossRef]
- Hofschulte-Beck, S.L.; Hickman, S.E.; Blackburn, J.L.; Mack, L.M.; Unroe, K.T. Attitudes and Experiences of Frontline Nursing Home Staff Toward Coronavirus Testing. J. Am. Med. Dir. Assoc. 2021, 22, 215–217. [Google Scholar] [CrossRef] [PubMed]
- Wanat, M.; Logan, M.; Hirst, J.; Vicary, C.; Lee, J.J.; Perera, R.; Tracey, I.; Duff, G.; Tuffano, P.; Fanshawe, T.R.; et al. Perceptions on undertaking regular asymptomatic self-testing for COVID-19 using lateral flow tests: A qualitative study of university students and staff. medRxiv 2021. [Google Scholar] [CrossRef]
- Ljubić, T.; Banovac, A.; Buljan, I.; Jerković, I.; Bašić, Ž.; Kružić, I.; Kolić, A.; Kolombatović, R.R.; Marušić, A.; Anđelinović, Š. Effect of SARS-CoV-2 antibody screening on participants’ attitudes and behaviour: A study of industry workers in Split, Croatia. Public Health 2021, 191, 11–16. [Google Scholar] [CrossRef]
- De Camargo, C. ‘It’s tough shit, basically, that you’re all gonna get it’: UK virus testing and police officer anxieties of contracting COVID-19. Polic. Soc. 2021, 1–17. [Google Scholar] [CrossRef]
- Knight, K.R.; Duke, M.R.; Carey, C.A. “This is about the coolest thing I’ve ever seen is that you just showed right up.” COVID-19 testing and vaccine acceptability among homeless-experienced adults: Qualitative data from two samples. medRxiv 2021. [Google Scholar] [CrossRef]
- McGowan, C.R.; Hellman, N.; Chowdhury, S.; Mannan, A.; Newell, K.; Cummings, R. COVID-19 testing acceptability and uptake amongst the Rohingya and host community in Camp 21, Teknaf, Bangladesh. Confl. Health 2020, 14, 74. [Google Scholar] [CrossRef] [PubMed]
- Kernberg, A.; Kelly, J.; Nazeer, S.; Russell, S.; Tuuli, M.; Stout, M.J.; Raghuraman, N.; Carter, E.B. Universal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Testing Uptake in the Labor and Delivery Unit: Implications for Health Equity. Obstet. Gynecol. 2020, 136, 1103–1108. [Google Scholar] [CrossRef]
- Ortega-Paredes, D.; Zurita, J.; Zurita, C.; Leoro-Garzón, P.; Leoro-Monroy, G.; Larrea-álvarez, C.M.; Loaiza, K.; Fernandez-Moreira, E.; Molina-Cuasapaz, G.; Larrea-álvarez, M. An on-line cross-sectional questionnaire to assess knowledge of COVID-19 pandemic among citizens tested for the SARS-CoV-2 virus in Quito and Ibarra, Ecuador. Int. J. Environ. Res. Public Health 2021, 18, 1691. [Google Scholar] [CrossRef]
- Smith, L.E.; Potts, H.W.W.; Amlôt, R.; Fear, N.T.; Michie, S.; Rubin, G.J. Adherence to the test, trace, and isolate system in the UK: Results from 37 nationally representative surveys. BMJ 2021, 372, n608. [Google Scholar] [CrossRef]
- Khalifa, A.M.; Alshammari, A.F.; Alrimali, A.M.; Alshammari, R.A. Willingness to Test for COVID-19: A Cross-Sectional Study on the Population in the Ha’il Region, KSA. J. Pharm. Res. Int. 2021, 33, 44–53. [Google Scholar] [CrossRef]
- Clipman, S.J.; Wesolowski, A.; Mehta, S.H.; Agarwal, S.; Cobey, S.E.; Cummings, D.A.T.; Gibson, D.G.; Labrique, A.B.; Kirk, G.D.; Solomon, S.S. SARS-CoV-2 testing in Florida, Illinois, and Maryland: Access and barriers. medRxiv 2020. [Google Scholar] [CrossRef]
- Bonner, C.; Batcup, C.; Ayre, J.; Pickles, K.; Dodd, R.; Copp, T.; Cornell, S.; Erin, C.; Dakin, T.; Isautier, J.; et al. Behavioural barriers to COVID-19 testing in Australia. medRxiv 2020. [Google Scholar] [CrossRef]
- Fabella, F.E. Factors Affecting Willingness to be tested for Covid-19. SSRN 2020. [Google Scholar] [CrossRef]
- Mcelfish, P.A.; Purvis, R.; James, L.P.; Willis, D.E. Perceived Barriers to COVID-19 Testing. Int. J. Environ. Res. Public Health 2021, 18, 2278. [Google Scholar] [CrossRef]
- Li, S.; Feng, B.; Liao, W.; Pan, W. Internet use, risk awareness, and demographic characteristics associated with engagement in preventive behaviors and testing: Cross-sectional survey on COVID-19 in the United States. J. Med. Internet Res. 2020, 22, e19782. [Google Scholar] [CrossRef] [PubMed]
- Thunström, L.; Ashworth, M.; Shogren, J.F.; Newbold, S.; Finnoff, D. Testing for COVID-19: Willful ignorance or selfless behavior? Behav. Public Policy 2021, 5, 135–152. [Google Scholar] [CrossRef]
- Oladoyin, V.O.; Okunlola, O.; Israel, O.; Ibirongbe, D.; Osifo, J.; Obembe, T.; Omode, P.; Osunmakinwa, O. Willingness of Nigerian residents to disclose COVID-19 symptoms and take COVID-19 test. medRxiv 2020. [Google Scholar] [CrossRef]
- Ferree, K.E.; Harris, A.S.; Dulani, B.; Kao, K.; Lust, E.; Metheney, E. Stigma, Trust, and procedural integrity: Covid-19 testing in Malawi. World Dev. 2021, 141, 105351. [Google Scholar] [CrossRef]
- Vandrevala, T.; Montague, A.; Terry, P.; Fielder, M. Willingness of the UK Public to Volunteer for Testing in Relation to the COVID-19 Pandemic. SSRN Electron. J. 2020. [Google Scholar] [CrossRef]
- Ali, S.H.; Tozan, Y.; Jones, A.M.; Foreman, J.; Capasso, A.; DiClemente, R.J. Regional and socioeconomic predictors of perceived ability to access coronavirus testing in the United States: Results from a nationwide online COVID-19 survey. Ann. Epidemiol. 2021, 58, 7–14. [Google Scholar] [CrossRef]
- Wallis, G.; Siracusa, F.; Blank, M.; Painter, H.; Sanchez, J.; Salinas, K.; Mamuyac, C.; Marudamuthu, C.; Wrigley, F.; Corrah, T.; et al. Experience of a novel community testing programme for COVID-19 in London: Lessons learnt. Clin. Med. J. R. Coll. Physicians Lond. 2020, 20, E165–E169. [Google Scholar] [CrossRef] [PubMed]
- Wu, D.C.; Jha, P.; Lam, T.; Brown, P.; Gelband, H.; Nagelkerke, N.; Birnboim, H.C.; Reid, A. Predictors of self-reported symptoms and testing for COVID-19 in Canada using a nationally representative survey. PLoS ONE 2020, 15, e0240778. [Google Scholar] [CrossRef]
- Dai, H.; Zhang, S.X.; Looi, K.H.; Su, R.; Li, J. Perception of health conditions and test availability as predictors of adults’ mental health during the covid-19 pandemic: A survey study of adults in Malaysia. Int. J. Environ. Res. Public Health 2020, 17, 5498. [Google Scholar] [CrossRef]
- Zhang, J.C.; Christensen, K.L.; Leuchter, R.K.; Vangala, S.; Han, M.; Croymans, D.M. The Role of Testing Availability on Intentions to Isolate during the COVID-19 Pandemic—A Randomized Trial. medRxiv 2021. [Google Scholar] [CrossRef]
- Lecouturier, J.; Kelly, M.P.; Graham, F.; Meyer, C.; Tang, M.Y.; Goffe, L.; Bonell, C.; Michie, S.; Sniehotta, F.F. Public understanding of COVID-19 antibody testing and test results: A qualitative study conducted in the U.K. early in the pandemic. Soc. Sci. Med. 2021, 273, 113778. [Google Scholar] [CrossRef] [PubMed]
- Zimba, R.; Kulkarni, S.; Berry, A.; You, W.; Mirzayi, C.; Westmoreland, D.; Parcesepe, A.; Waldron, L.; Rane, M.; Kochhar, S.; et al. SARS-CoV-2 testing service preferences of adults in the United States: Discrete choice experiment. JMIR Public Health Surveill. 2020, 6, e25546. [Google Scholar] [CrossRef]
- Siegler, A.J.; Hall, E.; Luisi, N.; Zlotorzynska, M.; Wilde, G.; Sanchez, T.; Bradley, H.; Sullivan, P.S. Willingness to seek diagnostic testing for SARS-CoV-2 with home, drive-through, and clinic-based specimen collection locations. Open Forum Infect. Dis. 2020, 7, ofaa269. [Google Scholar] [CrossRef]
- Atchison, C.; Pristerà, P.; Cooper, E.; Papageorgiou, V.; Redd, R.; Piggin, M.; Flower, B.; Fontana, G.; Satkunarajah, S.; Ashrafian, H.; et al. Usability and Acceptability of Home-based Self-testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies for Population Surveillance. Clin. Infect. Dis. 2021, 72, e384–e393. [Google Scholar] [CrossRef] [PubMed]
- Valentine-Graves, M.; Hall, E.; Guest, J.L.; Adam, E.; Valencia, R.; Shinn, K.; Hardee, I.; Sanchez, T.; Siegler, A.J.; Sullivan, P.S. At-home self-collection of saliva, oropharyngeal swabs and dried blood spots for sars-cov-2 diagnosis and serology: Postcollection acceptability of specimen collection process and patient confidence in specimens. PLoS ONE 2020, 15, e0236775. [Google Scholar] [CrossRef]
- Trudeau, J.M.; Alicea-Planas, J.; Vásquez, W.F. The value of COVID-19 tests in Latin America. Econ. Hum. Biol. 2020, 39, 100931. [Google Scholar] [CrossRef]
- Earnshaw, V.A.; Brousseau, N.M.; Hill, E.C.; Kalichman, S.C.; Eaton, L.A.; Fox, A.B. Anticipated Stigma, Stereotypes, and COVID-19 Testing. Stigma Health 2020, 5, 390–393. [Google Scholar] [CrossRef]
- UK Government Guidance on Protecting People Who Are Clinically Extremely Vulnerable from COVID-19. Available online: https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19 (accessed on 23 August 2021).
- Public Health England. Disparities in the risk and outcomes of COVID-19. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/908434/Disparities_in_the_risk_and_outcomes_of_COVID_August_2020_update.pdf (accessed on 1 September 2021).
- Napier, A.D. Rethinking vulnerability through Covid-19. Anthropol. Today 2020, 36, 1–2. [Google Scholar] [CrossRef] [PubMed]
- Gravlee, C.C. Systemic racism, chronic health inequities, and COVID-19: A syndemic in the making? Am. J. Hum. Biol. 2020, 32, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Team, V.; Manderson, L. How COVID-19 Reveals Structures of Vulnerability. Med. Anthropol. Cross Cult. Stud. Health Illn. 2020, 39, 671–674. [Google Scholar] [CrossRef]
- Osborne, J.; Paget, J.; Paget, J.; Giles-Vernick, T.; Kutalek, R.; Rodyna, R.; Ahmed, S.M.; Dückers, M. Addressing vulnerabilities in communities facing infectious disease threats: A need for social science-driven assessments. J. Glob. Health 2021, 11, 03003. [Google Scholar] [CrossRef] [PubMed]
- Quesada, J.; Hart, L.K.; Bourgois, P. Structural Vulnerability and Health: Latino Migrant Laborers in the United States. Med. Anthropol. 2011, 30, 339. [Google Scholar] [CrossRef] [Green Version]
- Hasell, J.; Mathieu, E.; Beltekian, D.; Macdonald, B.; Giattino, C.; Ortiz-Ospina, E.; Roser, M.; Ritchie, H. A cross-country database of COVID-19 testing. Sci. Data 2020, 7, 345. [Google Scholar] [CrossRef] [PubMed]
- Aristovnik, A.; Ravšelj, D.; Umek, L. A Bibliometric Analysis of COVID-19 across Science and Social Science Research Landscape. Sustainability 2020, 12, 9132. [Google Scholar] [CrossRef]
- Kavanagh, M.M.; Erondu, N.A.; Tomori, O.; Dzau, V.J.; Okiro, E.A.; Maleche, A.; Aniebo, I.C.; Rugege, U.; Holmes, C.B.; Gostin, L.O. Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. Lancet 2020, 395, 1735–1738. [Google Scholar] [CrossRef]
Authors | Methods/Site/Setting | Numbers of Participants | Target Population | Type of Test | Data Collection Period | Scope | Publication Stage |
---|---|---|---|---|---|---|---|
Ali et al. [56] | Methods: Cross-sectional survey Site: Community Setting: North America | 6378 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers | Published |
Allen et al. [31] | Methods: Longitudinal survey Site: Community Setting: North America | 4759 | National population; Service-users | Molecular | Qr2 2020 | Testing effects | Published |
Atchison et al. [64] | Methods: Focus groups; Interviews; Cross-sectional survey Site: Community Setting: Europe | 37 in focus groups; 25 interviewed; 11711 surveyed | National population | Antibody | Qr2 2020 | Facilitators/Barriers | Published |
Bender et al. [34] | Methods: Interviews; Cohort study; Cross-sectional survey Site: Institution Setting: North America | 318 surveyed; 242 interviewed | Vulnerable group (patient) | Molecular | Qr2 2020 | Testing effects | Published |
Blake et al. (1) [23] | Methods: Cross-sectional survey; Interviews; Focus groups Site: Institution Setting: Europe | 99 surveyed; 41 interviewed | Student and staff group | Antibody; Molecular | Qr4 2020 | Facilitators/Barriers; Testing effects | Published |
Blake et al. (2) [27] | Methods: Focus groups Site: Institution Setting: Europe | 25 | Student group | Antigen | Qr4 2020 | Facilitators/Barriers | Published |
Bonner et al. [48] | Methods: Longitudinal survey Site: Community Setting: Oceania | 1369 | National population | Molecular | Qr2 2020; Qr3 2020 | Facilitators/Barriers | Preprint |
Christensen et al. [28] | Methods: Interviews Site: Institution Setting: Europe | 15 | Service-users | Molecular | Qr2 2020; Qr3 2020 | Facilitators/Barriers; Testing effects | Published |
Clipman et al. [47] | Methods: Cross-sectional survey Site: Community Setting: North America | 3058 | Geographic sub-population | Molecular | Qr3 2020; Qr4 2020 | Facilitators/Barriers | Preprint |
Dai et al. [59] | Methods: Cross-sectional survey Site: Community Setting: Asia | 669 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers; Testing effects | Published |
De camargo [40] | Methods: Interviews site: Institution setting: Europe | 18 | Employment group | Antibody; Antigen; Molecular | Qr2 2020 | Facilitators/Barriers | Published |
Earnshaw et al. [67] | Methods: Cross-sectional survey Site: Community Setting: North America | 980 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers | Published |
Fabella [49] | Methods: Cross-sectional survey Site: Community Setting: Asia | 147 | National population | Unspecified | Qr3 2020 | Facilitators/Barriers | Preprint |
Ferree et al. [54] | Methods: Case-control survey Site: Community Setting: Africa | 4641 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers | Published |
Gillam et al. [25] | Methods: Cross-sectional survey Site: Institution Setting: Europe | 458 | Student group | Molecular | Unspecified | Facilitators/Barriers | Published |
Graham et al. [30] | Methods: Case-control survey Site: Community Setting: Europe; North America | 3193 | Service-users; Multi-country | Molecular | Qr1 2020; Qr2 2020; Qr3 2020; Qr4 2020 | Facilitators/Barriers | Preprint |
Hofschulte-Beck et al. [37] | Methods: Cross-sectional survey Site: Institution Setting: North America | 242 | Healthcare workers | Molecular | Qr2 2020 | Facilitators/Barriers | Published |
Kawamura et al. [35] | Methods: Cross-sectional survey Site: Institution Setting: Asia | 297 | Vulnerable group (patient); Healthcare workers | Molecular | Qr2 2020; Qr3 2020 | Testing effects | Published |
Kernberg et al. [43] | Methods: Time series of cross-sectional surveys Site: Institution Setting: North America | 270 | Vulnerable group (patient) | Unspecified | Qr2 2020 | Facilitators/Barriers | Published |
Khalifa et al. [46] | Methods: Cross-sectional survey Site: Community Setting: Asia | 664 | Geographic sub-population | Unspecified | Qr4 2020 | Facilitators/Barriers | Published |
Knight et al. [41] | Methods: Interviews Site: Community Setting: North America | 94 | Vulnerable group | Antigen; Molecular | Qr3 2020; Qr4 2020 | Facilitators/Barriers | Preprint |
Lan et al. [36] | Methods: Cross-sectional survey Site: Institution; Community Setting: Asia | 1167 | National population; Healthcare workers | Molecular; Antibody; Antigen | Qr2 2020; Qr3 2020 | Facilitators/Barriers; Testing effects | Published |
Lecouturier et al. [61] | Methods: Focus groups Site: Community Setting: Europe | 60 | National population | Antibody | Qr2 2020 | Facilitators/Barriers | Published |
Li et al. [51] | Methods: Cross-sectional survey Site: Community Setting: North America | 979 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers; Testing effects | Published |
Ljubic et al. [39] | Methods: Cross-sectional survey Site: Institution Setting: Europe | 200 | Employment group | Antibody | Qr2 2020 | Testing effects | Published |
Martin et al. [22] | Methods: Cross-sectional survey Site: Community Setting: Europe | 524 | Service-users | Antigen; Molecular | Qr4 2020; Qr1 2021 | Testing effects | Published |
Mcelfish et al. [50] | Methods: Cross-sectional survey Site: Community Setting: North America | 1221 | Geographic sub-population | Molecular | Qr3 2020 | Facilitators/Barriers | Published |
Mcgowan et al. [42] | Methods: Case-control survey Site: Community Setting: Asia | 222 | Vulnerable group | Unspecified | Qr3 2020; Qr4 2020 | Facilitators/Barriers | Published |
Missel et al. [33] | Methods: Interview Site: Institution Setting: Europe | 15 | Healthcare workers | Unspecified | Qr1 2020; Qr2 2020 | Facilitators/Barriers; Testing effects | Published |
Oladoyin et al. [53] | Methods: Cross-sectional survey Site: Community Setting: Africa | 524 | National population | Unspecified | Unspecified | Facilitators/Barriers | Preprint |
Ortega-Paredes et al. [44] | Methods: Cross-sectional survey Site: Community Setting: South America | 1656 | National population | Antibody; Antigen; Molecular | Qr3 2020 | Facilitators/Barriers | Published |
Packel et al. [26] | Methods: Cohort study; Cross-sectional survey Site: Institution Setting: North America | 2180 | Student group | Molecular | Qr2 2020; Qr3 2020 | Facilitators/Barriers | Published |
Ravert et al. [32] | Methods: Cross-sectional survey Site: Community Setting: North America | 178 | Age-based sub- population | Unspecified | Qr3 2020 | Facilitators/Barriers | Published |
Rojek et al. [29] | Methods: Cross-sectional survey Site: Community Setting: Oceania | 1846 | Patient group | Molecular | Qr1 2020 | Facilitators/Barriers | Published |
Siegler et al. [63] | Methods: Cross-sectional survey Site: Community Setting: North America | 1435 | National population | Unspecified | Qr1 2020 | Facilitators/Barriers | Published |
Smith et al. [45] | Methods: Time series of cross-sectional surveys Site: Community Setting: Europe | 53880 | National population | Antigen; Molecular | Qr1 2020; Qr2 2020; Qr3 2020; Qr4 2020 | Testing effects | Published |
Thunström et al. [52] | Methods: Cross-sectional survey Site: Community Setting: North America | 897 | National population | Unspecified | Unspecified | Facilitators/Barriers | Published |
Trudeau et al. [66] | Methods: Cross-sectional survey Site: Community Setting: South America | 5504 | Multi-country | Unspecified | Qr1 2020; Qr2 2020 | Facilitators/Barriers | Published |
Valentine-Graves et al. [65] | Methods: Cross-sectional survey Site: Community Setting: North America | 148 | National population | Antibody; Molecular | Unspecified | Facilitators/Barriers | Published |
Vandrevala et al. [55] | Methods: Cross-sectional survey Site: Community Setting: Europe | 778 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers | Preprint |
Wallis et al. [57] | Methods: Cross-sectional survey Site: Community Setting: Europe | 96 | Geographic sub-population | Molecular | Qr1 2020 | Testing effects | Published |
Wanat et al. [38] | Methods: Interviews; Cross-sectional survey Site: Institution Setting: Europe | 18 interviewed; 214 surveyed | Students and staff group; Service-users | Antigen | Qr4 2020; Qr1 2021 | Testing effects | Preprint |
Watson et al. [24] | Methods: Interviews; Focus groups Site: Community Setting: Europe | 223 | Geographic sub-population; Staff and student group | Molecular (RT-LAMP) | Qr2 2020; Qr3 2020; Qr4 2020 | Testing effects | Preprint |
Weiss et al. [21] | Methods: Cross-sectional survey Site: Community Setting: North America | 1421 | Health service users | Molecular | Unspecified | Facilitators/Barriers | Published |
Wu et al. [58] | Methods: Cross-sectional survey Site: Community Setting: North America | 4240 | National population | Molecular | Qr2 2020 | Facilitators/Barriers | Published |
Zhang et al. [60] | Methods: Case-control survey Site: Community Setting: North America | 1194 | National population | Unspecified | Qr3 2020 | Testing effects | Preprint |
Zimba et al. [62] | Methods: Discrete choice experiment Site: Community Setting: North America | 4793 | National population | Antibody; Antigen; Molecular | Qr3 2020 | Facilitators/Barriers | Published |
Themes | Findings | Studies |
---|---|---|
Test knowledge and symptom interpretation | General public has knowledge of main COVID-19 symptoms and/or testing types, uses, and accuracy. | Lan et al. (National pop/Healthcare workers China) Oladoyin et al. (National pop Nigeria) Ortega-Paredes et al. (National pop Ecuador) Fabella (National pop, Philippines) |
Patient interpretation of severity, type, and number of symptoms influences test-seeking behavior. Misrecognition or misattribution of symptoms to other causes is a barrier to testing. | Clipman et al. (Geographic sub pop, US) Fabella (National pop, Philippines) Graham et al. (Service-users, UK/US) Khalifa et al. (Geographic sub pop, Saudi Arabia) Mcgowan et al. (Vulnerable group, Bangladesh) Ortega-Paredes et al. (National pop Ecuador) Smith et al. (National pop, UK) | |
Perceived benefits of testing | To protect family, colleagues, and others in the community by reducing the spread of COVID-19. | Blake et al. (1) (Student and staff group, UK) Christensen et al. (Service-users, Denmark) De Camargo (Employment group, UK) Kawamura et al. (Patient group/Healthcare workers, Japan) Ljubić et al. (Employment group, Croatia) Lecouturier et al. (National pop, UK) Martin et al. (National pop, UK) Thunstrom et al. (National pop, US) Vandrevala et al. (National pop, UK) Wanat et al. (Student and staff group/service-users, UK) |
To be informed of one’s disease status. | Clipman et al. (Geographic sub pop, US) Lecouturier et al. (National pop, UK) Martin et al. (National pop, UK) | |
To contribute to scientific research and public management of the pandemic. | Blake et al. (1) (Student and staff group, UK) Lecouturier et al. (National pop, UK) Watson et al. (Geographic sub-pop/Staff and student group, UK) | |
Logistics of testing | Logistical issues, including not knowing where to go to get tested, lacking transport, perceptions of long waiting times, or test turnaround times are barriers to testing. | Clipman et al. (Geographic sub pop, US) Graham et al. (Service-users, UK/US) Mcelfish et al. (Geographic sub-population, US) Zimba et al. (National pop, US) |
COVID-19 self-test kits with different sample extraction methods (cheek swab or spit, pharyngeal swab, nasopharyngeal swab, fingerprick, DBS) are deemed usable and acceptable. | Atchison et al. (National pop, UK) Gillam et al. (Student group, UK) Martin et al. (National pop, UK) Siegler et al. (National pop, US) Valentine-Graves et al. (National pop, US) Zimba et al. (National pop, US) | |
People experience physical discomfort when using COVID-19 tests, in particular nasopharyngeal sampling methods. | Hofschulte-Beck et al. (Healthcare workers, US) Kawamura et al. (Patient group/Healthcare workers, Japan) Kernberg et al. (Patient group, US) Martin et al. (National pop, UK) Zimba et al. (National pop, US) | |
A wide variety of test sites (school/university, workplace, drive-thru, mobile testing services, home testing) are found to be convenient. Perceived convenience of testing site encourages uptake. | Blake et al. (2) (Student group, UK) Atchison et al. (National pop, UK) Gillam et al. (Student group, UK) Knight et al. (Vulnerable group, US) Siegler et al. (National pop, US) Weiss et al. (Health service-users, US) Zimba et al. (National pop, US) | |
Social pressures | Concerns about how employers, colleagues, or peers will react, or widespread disease stigma in some settings, are barriers to testing. | De Camargo (Employment group, UK) Earnshaw et al. (National pop, US) Ferree et al. (National pop, Malawi) Khalifa et al. (Geographic sub pop, Saudi Arabia) Smith et al. (National pop, UK) Wanat et al. (Student and staff group/service-users, UK) |
Endorsement from employers, educational institutions, peers, and/or colleagues encourages testing. | Blake et al. (1) (Student and staff group, UK) Missel et al. (Healthcare workers, Denmark) Packel et al. (Student group, US) Ravert et al. (Young adults, US) Watson et al. (Geographic sub-pop/Staff and student group, UK) | |
Financial burden of testing | No association between socioeconomic variables and people’s willingness to test. | Thunstrom et al. (National pop, US) Vandrevala et al. (National pop, UK) |
Perceptions of test affordability, costs of accessing testing, and/or costs associated with self-isolation are barriers to testing. | Ali et al. (National pop, US) Graham et al. (Service-users, UK/US) Hofschulte-Beck et al. (Healthcare workers, US) Smith et al. (National pop, UK) Watson et al. (Geographic sub-pop/Staff and student group, UK) | |
Trust | Lack of trust in government bodies to deliver and manage testing is a barrier to testing in some sub-populations. | Ferree et al. (National pop, Malawi) Mcgowan et al. (Vulnerable group, Bangladesh) Watson et al. (Geographic sub-pop/Staff and student group, UK) |
The accuracy and reliability of tests are a concern for some people, and in some instances, affect willingness to test. | Knight et al. (Vulnerable group, US) Lecouturier et al. (National pop, UK) | |
Vulnerable groups | Vulnerabilities relating to health, socioeconomic status, housing, or political status can prevent people from engaging with testing services. | Bender et al. (Vulnerable patient group, US) Bonner et al. (National pop, Australia) Kawamura et al. (Vulnerable patient group/Healthcare workers, Japan) Kernberg et al. (Vulnerable patient group, US) Knight et al. (Vulnerable group, US) |
Themes | Findings | Studies |
---|---|---|
Mental health and wellbeing | Testing is perceived as helpful for managing anxiety or fear. Receiving a negative test result is especially reassuring for individuals. | Dai et al. (National pop, Malaysia) Blake et al. (1) (Student and staff group, UK) De Camargo (Employment group, UK) Ljubić et al. (Employment group, Croatia) Kawamura et al. (Patient group/Healthcare workers, Japan) Wanat et al. (Student and staff group/service-users, UK) Watson et al. (Geographic sub-pop/Staff and student group, UK) |
Perceptions of testing as unavailable have negative effects on mental health. | Dai et al. (National pop, Malaysia) | |
Adherence to guidelines | People report high levels of adherence to guidelines on protective behaviors and/or express intentions to self-isolate should they receive a positive test result. | Christensen et al. (Service-users, Denmark) Missel et al. (Healthcare workers, Denmark) Li (National pop, US) Wallis et al. (Geographic sub-pop, UK) Wanat et al. (Student and staff group/service-users, UK) Zhang et al. (National pop, US) |
Some people find guidelines on self-isolation following a positive test result unclear or are practically unable to comply with these due to living arrangements or work. | Allen et al. (National pop/service-users, US) Blake et al. (2) (Student group, UK) Martin et al. (National pop, UK) Smith et al. (National pop, UK) | |
People report that they would not change their behavior or intend to do so following a negative test (or positive in the case of an antibody test result). | Lecouturier et al. (National pop, UK) Ljubić et al. (Employment group, Croatia) Wanat et al. (Student and staff group/service-users, UK) | |
Some people report engaging in riskier behaviors or intending to do so following a negative test result. | Martin et al. (National pop, UK) Zhang et al. (National pop, US) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bevan, I.; Stage Baxter, M.; Stagg, H.R.; Street, A. Knowledge, Attitudes, and Behavior Related to COVID-19 Testing: A Rapid Scoping Review. Diagnostics 2021, 11, 1685. https://doi.org/10.3390/diagnostics11091685
Bevan I, Stage Baxter M, Stagg HR, Street A. Knowledge, Attitudes, and Behavior Related to COVID-19 Testing: A Rapid Scoping Review. Diagnostics. 2021; 11(9):1685. https://doi.org/10.3390/diagnostics11091685
Chicago/Turabian StyleBevan, Imogen, Mats Stage Baxter, Helen R. Stagg, and Alice Street. 2021. "Knowledge, Attitudes, and Behavior Related to COVID-19 Testing: A Rapid Scoping Review" Diagnostics 11, no. 9: 1685. https://doi.org/10.3390/diagnostics11091685
APA StyleBevan, I., Stage Baxter, M., Stagg, H. R., & Street, A. (2021). Knowledge, Attitudes, and Behavior Related to COVID-19 Testing: A Rapid Scoping Review. Diagnostics, 11(9), 1685. https://doi.org/10.3390/diagnostics11091685